Literature DB >> 21346004

Influence of drug solubility and lipophilicity on transscleral retinal delivery of six corticosteroids.

Ashish Thakur1, Rajendra S Kadam, Uday B Kompella.   

Abstract

The influence of drug properties including solubility, lipophilicity, tissue partition coefficients, and in vitro transscleral permeability on ex vivo and in vivo transscleral delivery from corticosteroid suspensions was determined. Solubility, tissue/buffer partition coefficients for bovine sclera and choroid-retinal pigment epithelium (CRPE), and in vitro bovine sclera and sclera-choroid-retinal pigment epithelium (SCRPE) transscleral transport were determined at pH 7.4 for triamcinolone, prednisolone, dexamethasone, fluocinolone acetonide, triamcinolone acetonide, and budesonide in solution. Ex vivo and in vivo transscleral delivery was assessed in Brown Norway rats after posterior subconjunctival injection of a 1 mg/ml suspension of each corticosteroid. Corticosteroid solubility and partition coefficients ranged from ∼ 17 to 300 μg/ml and 3.0 to 11.4 for sclera and from 7.1 to 35.8 for CRPE, respectively, with the more lipophilic molecules partitioning more into both tissues. Transport across sclera and SCRPE was in the range of 3.9 to 10.7% and 0.3 to 1.8%, respectively, with the transport declining with an increase in lipophilicity. Ex vivo and in vivo transscleral delivery indicated tissue distribution in the order CRPE ≥ sclera > retina > vitreous. Tissue partitioning showed a positive correlation with drug lipophilicity (R(2) = 0.66-0.96). Ex vivo and in vivo sclera, CRPE, retina, and vitreous tissue levels of all corticosteroids showed strong positive correlation with drug solubility (R(2) = 0.91-1.0) but not lipophilicity (R(2) = 0.24-0.41) or tissue partitioning (R(2) = 0.24-0.46) when delivered as suspensions. In vivo delivery was lower in all eye tissues assessed than ex vivo delivery, with the in vivo/ex vivo ratios being the lowest in the vitreous (0.085-0.212). Upon exposure to corticosteroid suspensions ex vivo or in vivo, transscleral intraocular tissue distribution was primarily driven by the drug solubility.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21346004      PMCID: PMC3082374          DOI: 10.1124/dmd.110.037408

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  30 in total

1.  Dissolution of anecortave acetate in a cylindrical flow cell: re-evaluation of convective diffusion/drug dissolution for sparingly soluble drugs.

Authors:  Paul J Missel; L E Stevens; J W Mauger
Journal:  Pharm Dev Technol       Date:  2004-11       Impact factor: 3.133

Review 2.  Periocular routes for retinal drug delivery.

Authors:  Swita Raghava; Makena Hammond; Uday B Kompella
Journal:  Expert Opin Drug Deliv       Date:  2004-11       Impact factor: 6.648

3.  Size-dependent disposition of nanoparticles and microparticles following subconjunctival administration.

Authors:  Aniruddha C Amrite; Uday B Kompella
Journal:  J Pharm Pharmacol       Date:  2005-12       Impact factor: 3.765

4.  Triamcinolone acetonide with vitrectomy for treatment of macular edema associated with branch retinal vein occlusion.

Authors:  Akitaka Tsujikawa; Masashi Fujihara; Takuji Iwawaki; Kaoruko Yamamoto; Yasuo Kurimoto
Journal:  Retina       Date:  2005 Oct-Nov       Impact factor: 4.256

5.  Subconjunctivally administered celecoxib-PLGA microparticles sustain retinal drug levels and alleviate diabetes-induced oxidative stress in a rat model.

Authors:  Surya P Ayalasomayajula; Uday B Kompella
Journal:  Eur J Pharmacol       Date:  2005-03-28       Impact factor: 4.432

6.  Retinal delivery of celecoxib is several-fold higher following subconjunctival administration compared to systemic administration.

Authors:  Surya P Ayalasomayajula; Uday B Kompella
Journal:  Pharm Res       Date:  2004-10       Impact factor: 4.200

7.  In vitro human scleral permeability of fluorescein, dexamethasone-fluorescein, methotrexate-fluorescein and rhodamine 6G and the use of a coated coil as a new drug delivery system.

Authors:  Lars P J Cruysberg; Rudy M M A Nuijts; Dayle H Geroski; Leo H Koole; Fred Hendrikse; Henry F Edelhauser
Journal:  J Ocul Pharmacol Ther       Date:  2002-12       Impact factor: 2.671

8.  Controlled drug release from an ocular implant: an evaluation using dynamic three-dimensional magnetic resonance imaging.

Authors:  Hyuncheol Kim; Michael R Robinson; Martin J Lizak; Ginger Tansey; Robert J Lutz; Peng Yuan; Nam S Wang; Karl G Csaky
Journal:  Invest Ophthalmol Vis Sci       Date:  2004-08       Impact factor: 4.799

Review 9.  Binding of drugs to eye melanin is not predictive of ocular toxicity.

Authors:  B Leblanc; S Jezequel; T Davies; G Hanton; C Taradach
Journal:  Regul Toxicol Pharmacol       Date:  1998-10       Impact factor: 3.271

10.  Anecortave acetate as monotherapy for treatment of subfoveal neovascularization in age-related macular degeneration: twelve-month clinical outcomes.

Authors:  Donald J D'Amico; Morton F Goldberg; Henry Hudson; Janice A Jerdan; D Scott Krueger; Susan P Luna; Stella M Robertson; Stephen Russell; Lawrence Singerman; Jason S Slakter; Lawrence Yannuzzi; Patricia Zilliox
Journal:  Ophthalmology       Date:  2003-12       Impact factor: 12.079

View more
  16 in total

Review 1.  Therapeutic implications of nanomedicine for ocular drug delivery.

Authors:  Tuo Meng; Vineet Kulkarni; Russell Simmers; Vikram Brar; Qingguo Xu
Journal:  Drug Discov Today       Date:  2019-05-15       Impact factor: 7.851

2.  Sunitinib malate-loaded biodegradable microspheres for the prevention of corneal neovascularization in rats.

Authors:  Jin Yang; Lixia Luo; Yumin Oh; Tuo Meng; Guihong Chai; Shiyu Xia; David Emmert; Bing Wang; Charles G Eberhart; Seulki Lee; Walter J Stark; Laura M Ensign; Justin Hanes; Qingguo Xu
Journal:  J Control Release       Date:  2020-08-18       Impact factor: 9.776

3.  Brain mitochondrial drug delivery: influence of drug physicochemical properties.

Authors:  Shelley A Durazo; Rajendra S Kadam; Derek Drechsel; Manisha Patel; Uday B Kompella
Journal:  Pharm Res       Date:  2011-07-28       Impact factor: 4.200

4.  RETRACTED: Influence of choroidal neovascularization and biodegradable polymeric particle size on transscleral sustained delivery of triamcinolone acetonide.

Authors:  Rajendra S Kadam; Puneet Tyagi; Henry F Edelhauser; Uday B Kompella
Journal:  Int J Pharm       Date:  2012-05-23       Impact factor: 5.875

5.  Hydrophilic prodrug approach for reduced pigment binding and enhanced transscleral retinal delivery of celecoxib.

Authors:  Pradip Malik; Rajendra S Kadam; Narayan P S Cheruvu; Uday B Kompella
Journal:  Mol Pharm       Date:  2012-02-08       Impact factor: 4.939

6.  The effect of ocular pigmentation on transscleral delivery of triamcinolone acetonide.

Authors:  Wennan Du; Shumao Sun; Yu Xu; Jie Li; Chunhui Zhao; Bifei Lan; Hao Chen; Lingyun Cheng
Journal:  J Ocul Pharmacol Ther       Date:  2013-04-18       Impact factor: 2.671

7.  Controlled release of corticosteroid with biodegradable nanoparticles for treating experimental autoimmune uveitis.

Authors:  Lixia Luo; Jin Yang; Yumin Oh; Matthew J Hartsock; Shiyu Xia; Yoo-Chun Kim; Zheng Ding; Tuo Meng; Charles G Eberhart; Laura M Ensign; Jennifer E Thorne; Walter J Stark; Elia J Duh; Qingguo Xu; Justin Hanes
Journal:  J Control Release       Date:  2019-01-17       Impact factor: 9.776

Review 8.  Corticosteroids in ophthalmology: drug delivery innovations, pharmacology, clinical applications, and future perspectives.

Authors:  Sherif A Gaballa; Uday B Kompella; Omar Elgarhy; Ali M Alqahtani; Barbara Pierscionek; Raid G Alany; Hamdy Abdelkader
Journal:  Drug Deliv Transl Res       Date:  2021-06       Impact factor: 4.617

9.  Controllable continuous sub-tenon drug delivery of dexamethasone disodium phosphate to ocular posterior segment in rabbit.

Authors:  Xuetao Huang; Shaogang Liu; Yezhen Yang; Yiqin Duan; Ding Lin
Journal:  Drug Deliv       Date:  2017-11       Impact factor: 6.419

10.  Ion-Complex Microcrystal Formulation Provides Sustained Delivery of a Multimodal Kinase Inhibitor from the Subconjunctival Space for Protection of Retinal Ganglion Cells.

Authors:  Henry T Hsueh; Yoo-Chun Kim; Ian Pitha; Matthew D Shin; Cynthia A Berlinicke; Renee Ti Chou; Elizabeth Kimball; Julie Schaub; Sarah Quillen; Kirby T Leo; Hyounkoo Han; Amy Xiao; Youngwook Kim; Matthew Appell; Usha Rai; HyeYoung Kwon; Patricia Kolodziejski; Laolu Ogunnaike; Nicole M Anders; Avelina Hemingway; Joan L Jefferys; Abhijit A Date; Charles Eberhart; Thomas V Johnson; Harry A Quigley; Donald J Zack; Justin Hanes; Laura M Ensign
Journal:  Pharmaceutics       Date:  2021-05-01       Impact factor: 6.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.